Skip to main content
Premium Trial:

Request an Annual Quote

Genoox, Aspira Women's Health Partner to Develop New MDx Technologies

NEW YORK – Genoox said Thursday that it will partner with Aspira Women's Health to develop artificial intelligence and machine learning-driven technologies to improve molecular diagnosis and creation of treatment plans for conditions that affect women, particularly in the early stages of disease.

The firms are seeking to create new tests backed by data analysis by bringing together Aspira's biobank and algorithms, as well as Genoox's bioinformatics platform.

"This partnership will provide medical professionals with further information and tools to help women going through the most difficult periods of their lives, and also help both Genoox and Aspira expand our contributions to the medical and genomics industries," Genoox CEO and cofounder Amir Trabelsi said in a statement.

"Genoox and Aspira each seek to tackle the most difficult diseases in women's health, and this platform should allow us to reduce the development time for potentially groundbreaking data solutions," added Aspira CEO Valerie Palmieri. "Additionally, with this partnership, we are one step closer to our goal of closing the gap in ovarian cancer risk assessment and developing solutions for pelvic diseases combining genomics with proteomics."

Austin, Texas-based Aspira already has a collaborative research agreement with Baylor Genetics to develop an early detection test for ovarian cancer.

Palo Alto, California-based genomic analysis firm Genoox closed an $8 million funding round earlier this year and announced plans to expand the reach of its technology, which provides machine learning to analyze large amounts of genetic data from next-generation sequencing.